Biolojic Design has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune disease. Financial terms of the transaction were not disclosed.
“Our AI-based platform designs mono- and multi-specific human antibodies that target pre-determined epitopes with exquisite precision and executes functions previously not able to be carried out with antibodies,” said Yanay Ofran, Ph.D., Chief Executive Officer of Biolojic. “We look forward to working with Nektar, who has a deep understanding of the biological and clinical requirements for this new target.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“This research collaboration with Biolojic allows us to leverage their unique computational capabilities and assets in order to investigate a new target in the potential treatment of auto-immune disease,” said Jonathan Zalevsky, Chief Research and Development Officer of Nektar. “Our research team looks forward to collaborating with them on this program.”